Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

Next Previous
Trial Profile

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Nezastomig (Primary) ; Nezastomig (Primary) ; REGN 4336 (Primary) ; Piflufolastat F18
  • Indications Adenocarcinoma; Prostate cancer; Renal cell carcinoma
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 30 Apr 2025 Updated results (data cutoff date: 26 Feb 2024; n=78) reporting safety, new survival and biomarker analysis data presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 05 Mar 2024 Number of treatment arms increased from 3 to 4 by the addition of one more dose escalation arm.
  • 05 Mar 2024 Planned number of patients changed from 297 to 345.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top